Search Results For ''

  • Can Medibio’s software redefine mental health diagnostics?

    Mental illness will have an impact on 45% of Australians at some point in their lifetime. While the world is becoming increasingly aware of mental health conditions, little is being done to redefine the diagnostics. Currently, the gold standard in the diagnosis of mental illness is The Diagnostic and Statistical Manual of Mental Disorders (DSM5).

    Read More
    Public
  • Mobecom adds Coles, Kmart, Bunnings and more as clients with Neat Ideas acquisition

    A power balance is in the process of shifting in the retail world where brand loyalty is one of the most valuable assets a consumer owns, often unknown to the consumer themselves. Identifying this changing trend, eCommerce company Mobecom (ASX: MBM) has acquired rewards business Neat Ideas to enhance their customer engagement platform.  Core to

    Read More
    Public
  • Top ASX small caps fund eyes growth in this fintech with $3.5m on-market buying

    As one of Australia’s most successful funds in the small cap space returning more than 100% in the past 12 months, savvy investors may be intrigued to see Microequities has progressively increased their holding in one fintech company over the past 12 months.  Specialising in the small caps sector, the Microequities Pure Microcap Value Fund

    Read More
    Public
  • Ingenia are not taking a break, so you can

    Australian’s are slowly pulling down their masks to embrace a new normal in the wake of the pandemic. Travel, at least domestically, is returning to pre-covid levels, a welcome change for those working in and around one of the hardest hit industries. Amongst those relieved companies is Ingenia Communities (ASX: INA). The Company is welcoming

    Read More
    Public
  • Lending giant secures stake in Novatti neobank with $18m funding commitment

    Having built one of the most comprehensive networks of banking service partners over the past two years, digital payments company Novatti Group (ASX: NOV) has been noticed on the global stage, securing $18 million in funding for the launch of their planned neobank.  The funding commitment comes from BC Investment Group (BC Invest) which offers

    Read More
    Public
  • Charlie Teo Foundation backs Pharmaxis with brain cancer research funding

    Killing more children than any other disease, the average survival rate after diagnosis of brain cancer is only 15 months. But that could soon change with the Charlie Teo Foundation funding new research into a drug developed by Aussie pharmaceuticals company Pharmaxis (ASX: PXS) to tackle glioblastoma, the most common form of brain cancer. The

    Read More
    Public